{"id":"NCT01298219","sponsor":"Sucampo Pharma Americas, LLC","briefTitle":"Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)","officialTitle":"A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Subjects With Opioid-induced Bowel Dysfunction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2011-11","completion":"2011-11","firstPosted":"2011-02-17","resultsPosted":"2019-12-24","lastUpdate":"2020-02-11"},"enrollment":439,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Opioid-induced Bowel Dysfunction"],"interventions":[{"type":"DRUG","name":"Lubiprostone","otherNames":["Amitiza"]},{"type":"DRUG","name":"Placebo","otherNames":["No other names"]}],"arms":[{"label":"Lubiprostone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of the study is to evaluate the efficacy and safety of lubiprostone administration in subjects with Opioid-induced Bowel Dysfunction.","primaryOutcome":{"measure":"Number of Participants Classified as Treatment Responders Within 12 Weeks","timeFrame":"12 weeks","effectByArm":[{"arm":"Lubiprostone","deltaMin":59,"sd":null},{"arm":"Placebo","deltaMin":41,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":1},"locations":{"siteCount":142,"countries":["United States","Belgium","Czechia","Germany","Poland","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":219},"commonTop":["Diarrhea","Nausea","Vomiting","Abdominal Pain","Urinary Tract Infection"]}}